Cellular senescence drives both acute kidney injury and chronic kidney disease progression, but current senolytic drugs only partially slow disease advancement while risking adverse effects. This comprehensive analysis reveals that combination therapies targeting senescence, inflammation, and tissue damage simultaneously may overcome these limitations. The approach leverages longevity proteins α-klotho and SIRT1 alongside extracellular vesicles to regulate cellular senescence and reduce kidney fibrosis. This multi-modal strategy represents a paradigm shift from current single-target treatments that have shown limited efficacy in kidney disease management. The kidney's unique vulnerability to senescence makes it an ideal testing ground for next-generation anti-aging therapeutics. Unlike previous approaches that focus solely on clearing senescent cells, this integrative framework addresses the complex interplay between aging pathways, inflammatory cascades, and tissue repair mechanisms. For the 37 million Americans with chronic kidney disease, this could herald more effective treatments that address root causes rather than symptoms. However, translating these preclinical insights into human therapies remains challenging, requiring careful optimization of drug combinations and delivery methods.